Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?

Translational Stroke Research

Volumn 7, Issue 5, 2016, Pages 415-419

  Xia, Yuguo ^a   Cai, Wei ^a   Thomson, Angus W ^b   Hu, Xiaoming ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; CELL FUNCTION; CELL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; EDITORIAL; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MOLECULAR MECHANICS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TRANSLATIONAL RESEARCH; CEREBROVASCULAR ACCIDENT; IMMUNOTHERAPY;

BRAIN ISCHEMIA; HUMANS; IMMUNOTHERAPY; STROKE; T-LYMPHOCYTES, REGULATORY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84974800538     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0476-4     Document Type: Editorial

References (60)

1. Romano JG, Sacco RL. Decade in review-stroke: progress in acute ischaemic stroke treatment and prevention. Nat Rev Neurosci. 2015;11(11):619–21. doi:10.1038/nrneurol.2015.199.
2. O’Bryant Z, Vann KT, Xiong ZG. Translational strategies for neuroprotection in ischemic stroke—focusing on acid-sensing ion channel 1a. Transl Stroke Res. 2014;5(1):59–68. doi:10.1007/s12975-013-0319-5.
3. Lapchak PA. A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. Transl Stroke Res. 2015;6(2):99–103. doi:10.1007/s12975-015-0386-x.
4. Seifert HA, Pennypacker KR. Molecular and cellular immune responses to ischemic brain injury. Transl Stroke Res. 2014;5(5):543–53. doi:10.1007/s12975-014-0349-7.
5. An C, Shi Y, Li P, Hu X, Gan Y, Stetler RA, et al. Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair. Prog Neurobiol. 2014;115:6–24. doi:10.1016/j.pneurobio.2013.12.002.
6. Chen S, Yang Q, Chen G, Zhang JH. An update on inflammation in the acute phase of intracerebral hemorrhage. Transl Stroke Res. 2015;6(1):4–8. doi:10.1007/s12975-014-0384-4.
7. Hosaka K, Hoh BL. Inflammation and cerebral aneurysms. Transl Stroke Res. 2014;5(2):190–8. doi:10.1007/s12975-013-0313-y.
8. Pennypacker KR. Targeting the peripheral inflammatory response to stroke: role of the spleen. Transl Stroke Res. 2014;5(6):635–7. doi:10.1007/s12975-014-0372-8.
9. Benakis C, Brea D, Caballero S, Faraco G, Moore J, Murphy M, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal gammadelta T cells. Nat Med. 2016;22(5):516–23. doi:10.1038/nm.4068.
10. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al. Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurosci. 2015;11(1):56–64. doi:10.1038/nrneurol.2014.207.
11. Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, et al. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res. 2015;6(1):60–8. doi:10.1007/s12975-014-0373-7.
12. Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ. Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke. Transl Stroke Res. 2014;5(5):612–7. doi:10.1007/s12975-014-0348-8.
13. Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, et al. Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res. 2014;5(5):577–85. doi:10.1007/s12975-014-0345-y.
14. Li P Gan Y, Sun BL, Zhang F, B Lu, Y Gao, W Liang, AW Thomson, J Chen and X Hu. Adoptive regulatory T cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74(3):458–71. doi:10.1002/ana.23815.
15. Wang J, Xie L, Yang C, Ren C, Zhou K, Wang B, et al. Activated regulatory T cell regulates neural stem cell proliferation in the subventricular zone of normal and ischemic mouse brain through interleukin 10. Front Cell Neurosci. 2015;9:361. doi:10.3389/fncel.2015.00361.
16. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15(2):192–9.
17. Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci: Off J Soc Neurosci. 2011;31(23):8556–63. doi:10.1523/JNEUROSCI.1623-11.2011.
18. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis. 2014;29(1):59–73. doi:10.1007/s11011-013-9474-3.
19. Offner H, Hurn PD. A novel hypothesis: regulatory B lymphocytes shape outcome from experimental stroke. Transl Stroke Res. 2012;3(3):324–30. doi:10.1007/s12975-012-0187-4.
20. Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. CD4 + FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metab Brain Dis. 2011;26(1):87–90. doi:10.1007/s11011-010-9226-6.
21. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121(4):679–91. doi:10.1182/blood-2012-04-426734.
22. Liesz A, Kleinschnitz C, Regulatory T. Cells in post-stroke immune homeostasis. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0465-7.
23. Liesz A, Hu X, Kleinschnitz C, Offner H. Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke J Cereb Circ. 2015;46(5):1422–30. doi:10.1161/STROKEAHA.114.008608.
24. Theil A, Tuve S, Oelschlagel U, Maiwald A, Dohler D, Ossmann D, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473–86. doi:10.1016/j.jcyt.2014.11.005.
25. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–70. doi:10.1182/blood-2010-07-293795.
26. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009;133(1):22–6. doi:10.1016/j.clim.2009.06.001.
27. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8. doi:10.1182/blood-2010-10-311894.
28. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, et al. Administration of CD4 + CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2012;35(9):1817–20. doi:10.2337/dc12-0038.
29. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science translational medicine. 2015;7(315):315ra189. doi:10.1126/scitranslmed.aad4134.
30. Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T cell-based cell therapy in living donor liver transplantation. Hepatology. 2016. doi:10.1002/hep.28459.
31. Yan J, Greer JM, Etherington K, Cadigan GP, Cavanagh H, Henderson RD, et al. Immune activation in the peripheral blood of patients with acute ischemic stroke. J Neuroimmunol. 2009;206(1–2):112–7.
32. Urra X, Cervera A, Villamor N, Planas AM, Chamorro A. Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience. 2009;158(3):1174–83.
33. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab. 2009;29(3):606–20.
34. Li P, Mao L, Liu X, Gan Y, Zheng J, Thomson AW, et al. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke. Stroke J Cereb Circ. 2014;45(3):857–64. doi:10.1161/STROKEAHA.113.004100.
35. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4 + CD25 + FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338–47.
36. Trzonkowski P, Szarynska M, Mysliwska J, Mysliwski A. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A: J Int Soc Anal Cytol. 2009;75(3):175–88. doi:10.1002/cyto.a.20659.
37. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455–65.
38. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4 + CD25+ regulatory T cells promote experimental transplantation tolerance. Blood. 2007;109(2):827–35.
39. Rossetti M, Spreafico R, Saidin S, Chua C, Moshref M, Leong JY, et al. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J Immunol. 2015;194(1):113–24. doi:10.4049/jimmunol.1401145.
40. Zhang H, Guo H, Lu L, Zahorchak AF, Wiseman RW, Raimondi G, et al. Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates. Am J Transplant. 2015;15(5):1253–66. doi:10.1111/ajt.13113.
41. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41. doi:10.1126/scitranslmed.3001809.
42. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 2008;112(7):2847–57. doi:10.1182/blood-2008-01-132951.
43. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, et al. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014;16(1):90–100. doi:10.1016/j.jcyt.2013.07.009.
44. Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, et al. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4 + CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Transfusion. 2012;52(6):1333–47. doi:10.1111/j.1537-2995.2011.03448.x.
45. Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 2012;33(12):626–32. doi:10.1016/j.it.2012.07.007.
46. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009;206(4):751–60. doi:10.1084/jem.20082824.
47. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055–66. doi:10.1056/NEJMoa1108188.
48. Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood. 2015;126(4):546–57. doi:10.1182/blood-2015-04-637587.
49. Wolf D, Schreiber TH, Tryphonopoulos P, Li S, Tzakis AG, Ruiz P, et al. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation. 2012;94(6):569–74. doi:10.1097/TP.0b013e318264d3ef.
50. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9(6):676–83. doi:10.1038/ni.1615.
51. Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, et al. Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol. 2013;43(2):533–9. doi:10.1002/eji.201242603.
52. Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A. Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood. 2009;113(25):6277–87. doi:10.1182/blood-2008-06-161026.
53. Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, et al. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4 + CD25 + FoxP3+ Treg. Blood. 2015;125(19):2937–47. doi:10.1182/blood-2014-09-599266.
54. Li P, Mao L, Zhou G, Leak RK, Sun BL, Chen J, et al. Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. Stroke. 2013;44(12):3509–15. doi:10.1161/STROKEAHA.113.002637.
55. Zheng SG, Wang J, Horwitz DA. Cutting edge: Foxp3 + CD4 + CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol. 2008;180(11):7112–6.
56. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One. 2011;6(1):e15868. doi:10.1371/journal.pone.0015868.
57. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17(7):796–808. doi:10.1038/nm.2399.
58. Gonzalez-Moreno EI, Camara-Lemarroy CR, Gonzalez-Gonzalez JG, Gongora-Rivera F. Glycemic variability and acute ischemic stroke: the missing link? Transl Stroke Res. 2014;5(6):638–46. doi:10.1007/s12975-014-0365-7.
59. Suenaga J, Hu X, Pu H, Shi Y, Hassan SH, Xu M, et al. White matter injury and microglia/macrophage polarization are strongly linked with age-related long-term deficits in neurological function after stroke. Exp Neurol. 2015;272:109–19. doi:10.1016/j.expneurol.2015.03.021.
60. Ergul A, Hafez S, Fouda A, Fagan SC. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0464-8.